Is intravenous lorazepam really more effective and safe than intravenous diazepam as first-line treatment for convulsive status epilepticus? A systematic review with meta-analysis of randomized controlled trials

Epilepsy and Behavior

Volumn 64, Issue , 2016, Pages 29-36

  Brigo, Francesco ^a,b   Bragazzi, Nicola Luigi ^c   Bacigaluppi, Susanna ^d   Nardone, Raffaele ^b,e   Trinka, Eugen ^e,f,g  

^a UNIVERSITY OF VERONA   (Italy)

^b FRANZ TAPPEINER HOSPITAL   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d GALLIERA HOSPITAL   (Italy)

^e PARACELSUS MEDICAL UNIVERSITY   (Austria)

^f UNIVERSITY OF SALZBURG   (Austria)

^g UNIVERSITY FOR HEALTH SCIENCES   (Austria)

Author keywords

Diazepam; Efficacy; Lorazepam; Meta analysis; Status epilepticus

Indexed keywords

DIAZEPAM; LORAZEPAM; ANTICONVULSIVE AGENT;

ARTIFICIAL VENTILATION; DISEASE CONTROL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPILEPTIC STATE; HEART ARRHYTHMIA; HUMAN; HYPOTENSION; MANTEL HAENSZEL TEST; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEIZURE; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; INTRAVENOUS DRUG ADMINISTRATION; SEIZURES; STATUS EPILEPTICUS; TREATMENT OUTCOME;

ADMINISTRATION, INTRAVENOUS; ANTICONVULSANTS; DIAZEPAM; HUMANS; LORAZEPAM; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEIZURES; STATUS EPILEPTICUS; TREATMENT OUTCOME;

EID: 84991444258     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2016.09.020     Document Type: Review

References (49)

1. [1] Ong, C.T., Wong, Y.S., Sung, S.F., Wu, C.S., Hsu, Y.C., Su, Y.H., et al. Underestimated rate of status epilepticus according to the traditional definition of status epilepticus. ScientificWorldJournal, 2015, 2015, 801834.
2. [2] Hesdorffer, D.C., Logroscino, G., Cascino, G., Annegers, J.F., Hauser, W.A., Incidence of status epilepticus in Rochester, Minnesota, 1965–1984. Neurology 50:3 (1998), 735–741.
3. [3] Betjemann, J.P., Lowenstein, D.H., Status epilepticus in adults. Lancet Neurol 14:6 (2015), 615–624.
4. [4] Rosenow, F., Hamer, H.M., Knake, S., The epidemiology of convulsive and nonconvulsive status epilepticus. Epilepsia 48:Suppl. 8 (2007), 82–84.
5. [5] Trinka, E., Höfler, J., Leitinger, M., Brigo, F., Pharmacotherapy for status epilepticus. Drugs 75:13 (2015), 1499–1521.
6. [6] Trinka, E., Cock, H., Hesdorffer, D., Rossetti, A.O., Scheffer, I.E., Shinnar, S., et al. A definition and classification of status epilepticus — report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia 56:10 (2015), 1515–1523.
7. [7] Theodore, W.H., Porter, R.J., Albert, P., Kelley, K., Bromfield, E., Devinsky, O., et al. The secondarily generalized tonic–clonic seizure: a videotape analysis. Neurology 44:8 (1994), 1403–1407.
8. [8] Shinnar, S., Berg, A.T., Moshe, S.L., Shinnar, R., How long do new-onset seizures in children last?. Ann Neurol 49:5 (2001), 659–664.
9. [9] Jenssen, S., Gracely, E.J., Sperling, M.R., How long do most seizures last? A systematic comparison of seizures recorded in the epilepsy monitoring unit. Epilepsia 47:9 (2006), 1499–1503.
10. [10] Dobesberger, J., Ristić, A.J., Walser, G., Kuchukhidze, G., Unterberger, I., Höfler, J., et al. Duration of focal complex, secondarily generalized tonic–clonic, and primarily generalized tonic–clonic seizures—a video-EEG analysis. Epilepsy Behav 49 (2015), 111–117.
11. [11] Trinka, E., Brigo, F., Benzodiazepines used in the treatment of epilepsy. Shorvon, S., P E., Engel, J., (eds.) The treatment of epilepsy, 4th ed., 2015, Wyley, Chichester, UK, 398–417.
12. [12] Shorvon, S., Baulac, M., Cross, H., Trinka, E., Walker, M., Task force on status epilepticus of the ILAE Commission for European Affairs. The drug treatment of status epilepticus in Europe: consensus document from a workshop at the first London colloquium on status epilepticus. Epilepsia 49:7 (2008), 1277–1285.
13. [13] Alvarez, V., Lee, J.W., Drislane, F.W., Westover, M.B., Novy, J., Dworetzky, B.A., et al. Practice variability and efficacy of clonazepam, lorazepam, and midazolam in status epilepticus: a multicenter comparison. Epilepsia 56:8 (2015), 1275–1285.
14. [14] Navarro, V., Dagron, C., Elie, C., Lamhaut, L., Demeret, S., Urien, S., et al. Prehospital treatment with levetiracetam plus clonazepam or placebo plus clonazepam in status epilepticus (SAMUKeppra): a randomised, double-blind, phase 3 trial. Lancet Neurol 15:1 (2016), 47–55.
15. [15] Schütz, H., Benzodiazepines, I.I., A handbook. Basic data, analytical methods, pharmacokonetics, and comprehensive literature. 1989, Springer, Heidelberg, New York.
16. [16] Greenblatt, D.J., Divoll, M., Diazepam versus lorazepam: relationship of drug distribution to duration of clinical action. Escueta, A.V.D., Wasterlain, C.G., Treiman, D.M., Porter, R.J., (eds.) Status epilepticus: mechanisms of brain damage and treatment Advances in Neurology, vol. 34, 1983, Raven Press, New York, 487–491.
17. [17] Friedman, H., Ochs, H.R., Greenblatt, D.J., Shader, R.I., Tissue distrubtion of diazepam and its metabolite desmethyldiazepam: a human autopsy study. J Clin Pharmacol 25 (1985), 613–615.
18. [18] Minicucci, F., Muscas, G., Perucca, E., Capovilla, G., Vigevano, F., Tinuper, P., Treatment of status epilepticus in adults: guidelines of the Italian League Against Epilepsy. Epilepsia 47:Suppl. 5 (2006), 9–15.
19. [19] Brophy, G.M., Bell, R., Claassen, J., Alldredge, B., Bleck, T.P., Glauser, T., et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care 17:1 (2012), 3–23.
20. [20] Riviello, J.J. Jr., Claassen, J., LaRoche, S.M., Sperling, M.R., Alldredge, B., Bleck, T.P., et al. Treatment of status epilepticus: an international survey of experts. Neurocrit Care 18:2 (2013), 193–200.
21. [21] WHO, Mental health gap action programme. http://www.who.int/mental_health/mhgap/evidence/resource/epilepsy_q2.pdf?ua=1, 2015 [accessed November 27, 2015].
22. [22] Lowenstein, D.H., Bleck, T., Macdonald, R.L., It's time to revise the definition of status epilepticus. Epilepsia 40 (1999), 120–122.
23. [23] Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., PRISMA Group, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med, 6(6), 2009, e1000097.
24. [24] Higgins, J.P.T., Green, S., (eds.) Handbook for systematic reviews of interventions version 5.1.0 (updated march 2011), 2011, The Cochrane Collaboration.
25. [25] DerSimonian, R., Laird, N., Meta-analysis in clinical trials. Control Clin Trials 7 (1986), 177–188.
26. [26] Higgins, J.P., Thompson, S.G., Deeks, J.J., Altman, D.G., Measuring inconsistency in meta-analyses. BMJ 327 (2003), 557–560.
27. [27] Treiman, D.M., Meyers, P.D., Walton, N.Y., Collins, J.F., Colling, C., Rowan, A.J., et al. A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med 339:12 (1998), 792–798.
28. [28] Sreenath, T.G., Gupta, P., Sharma, K.K., Krishnamurthy, S., Lorazepam versus diazepam-phenytoin combination in the treatment of convulsive status epilepticus in children: a randomized controlled trial. Eur J Paediatr Neurol 14:2 (2010), 162–168.
29. [29] Leppik, I.E., Derivan, A.T., Homan, R.W., Walker, J., Ramsay, R.E., Patrick, B., Double-blind study of lorazepam and diazepam in status epilepticus. JAMA 249:11 (1983), 1452–1454.
30. [30] Appleton, R., Sweeney, A., Choonara, I., Robson, J., Molyneux, E., Lorazepam versus diazepam in the acute treatment of epileptic seizures and status epilepticus. Dev Med Child Neurol 37:8 (1995), 682–688.
31. [31] Alldredge, B.K., Gelb, A.M., Isaacs, S.M., Corry, M.D., Allen, F., Ulrich, S., et al. A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. N Engl J Med 345:9 (2001), 631–637.
32. [32] Gathwala, G., Goel, M., Singh, J., Mittal, K., Intravenous diazepam, midazolam and lorazepam in acute seizure control. Indian J Pediatr 79:3 (2012), 327–332.
33. [33] Chamberlain, J.M., Okada, P., Holsti, M., Mahajan, P., Brown, K.M., Vance, C., et al. Lorazepam vs diazepam for pediatric status epilepticus: a randomized clinical trial. JAMA 311:16 (2014), 1652–1660.
34. [34] Prasad, M., Krishnan, P.R., Sequeira, R., Al-Roomi, K., Anticonvulsant therapy for status epilepticus. Cochrane Database Syst Rev, 9, 2014, CD003723.
35. [35] Giang, D.W., McBride, M.C., Lorazepam versus diazepam for the treatment of status epilepticus. Pediatr Neurol 4:6 (1988), 358–361.
36. [36] Cock, H.R., Schapira, A.H., A comparison of lorazepam and diazepam as initial therapy in convulsive status epilepticus. QJM 95:4 (2002), 225–231.
37. [37] Qureshi, A., Wassmer, E., Davies, P., Berry, K., Whitehouse, W.P., Comparative audit of intravenous lorazepam and diazepam in the emergency treatment of convulsive status epilepticus in children. Seizure 11:3 (2002 Apr), 141–144.
38. [38] Vinks, A.A., Saldana, S.N., Walson, P.D., Developmental principles of pharmacokinetics. Martin, A., Scahill, L., Kratochvil, C.J., (eds.) Pediatric psychopharmacology. Principles and practice, 2nd ed., 2013, Oxford, 44.
39. [39] Fetner, H.H., Geller, B., Lithium and tricyclic antidepressants. Psychiatr Clin North Am 15:1 (1992), 223–224.
40. [40] Chamberlain, J.M., Capparelli, E.V., Brown, K.M., Vance, C.W., Lillis, K., Mahajan, P., et al. Pharmacokinetics of intravenous lorazepam in pediatric patients with and without status epilepticus. J Pediatr 160:4 (2012), 667–672.
41. [41] Towne, A.R., Pellock, J.M., Ko, D., DeLorenzo, R.J., Determinants of mortality in status epilepticus. Epilepsia 35:1 (1994), 27–34.
42. [42] Rossetti, A.O., Hurwitz, S., Logroscino, G., Bromfield, E.B., Prognosis of status epilepticus: role of aetiology, age, and consciousness impairment at presentation. J Neurol Neurosurg Psychiatry 77:5 (2006), 611–615.
43. [43] Neligan, A., Shorvon, S.D., Frequency and prognosis of convulsive status epilepticus of different causes: a systematic review. Arch Neurol 67:8 (2010), 931–940.
44. [44] Neligan, A., Shorvon, S.D., Prognostic factors, morbidity and mortality in tonic–clonic status epilepticus: a review. Epilepsy Res 93:1 (2011), 1–10.
45. [45] Silbergleit, R., Durkalski, V., Lowenstein, D., Conwit, R., Pancioli, A., Palesch, Y., et al. Intramuscular versus intravenous therapy for prehospital status epilepticus. N Engl J Med 366:7 (2012), 591–600.
46. [46] Trinka, E., Brigo, F., Shorvon, S., Recent advances in status epilepticus. Curr Opin Neurol 29:2 (2016), 189–198.
47. [47] Trinka, E., Höfler, J., Leitinger, M., Rohracher, A., Kalss, G., Brigo, F., Pharmacologic treatment of status epilepticus. Expert Opin Pharmacother 17:4 (2016), 513–534.
48. [48] Brigo, F., Nardone, R., Tezzon, F., Trinka, E., Nonintravenous midazolam versus intravenous or rectal diazepam for the treatment of early status epilepticus: a systematic review with meta-analysis. Epilepsy Behav 49 (2015), 325–336.
49. [49] Brigo, F., Storti, M., Del Felice, A., Fiaschi, A., Bongiovanni, L.G., IV valproate in generalized convulsive status epilepticus: a systematic review. Eur J Neurol 19:9 (2012), 1180–1191.